Abbott Laboratories (ABT) Common Equity (2009 - 2026)

Abbott Laboratories has disclosed Common Equity across 18 years of filings, most recently posting $52.7 billion for Q1 2026.

• Common Equity for Q1 2026 came in at $52.7 billion, up 9170.74% year-over-year; the trailing twelve-month figure through Mar 2026 was $52.7 billion (up 9170.74% YoY), and the FY2025 annual result was $52.1 billion, up 107.25% from the prior year.
• Common Equity came in at $52.7 billion for Q1 2026 at Abbott Laboratories, up from $52.1 billion in the prior quarter.
• In the past five years, Common Equity ranged from a high of $52.7 billion in Q1 2026 to a low of -$8.7 billion in Q2 2022.
• The 5-year median for Common Equity is $24.9 billion (2024), against an average of $20.0 billion.
• Across the five-year window, Common Equity slumped 8783.67% in 2022 and soared 30897.47% in 2023, its largest moves.
• Abbott Laboratories' Common Equity stood at $35.3 billion in 2022, then fell by 29.46% to $24.9 billion in 2023, then grew by 1.14% to $25.2 billion in 2024, then jumped by 107.25% to $52.1 billion in 2025, then grew by 1.1% to $52.7 billion in 2026.
• The last three Common Equity figures came in at $52.7 billion (Q1 2026), $52.1 billion (Q4 2025), and $51.0 billion (Q3 2025), per Business Quant data.